|
(V37) |
Platelet-mediated activation of FasR and subsequent phosphatidylserine exposure of red blood cells is substantial for thrombus formation and hemostasis |
| |
|
M. Elvers, C. Klatt, S. Zey, N. S. Gowert, A. Oberhuber, M. Schaller, H. Schelzig (Düsseldorf, Tübingen) |
|
|
Diskussion |
|
(V38) |
Clot structure predicts mortality in chronic kidney disease: a role for posttranslational modifications of fibrinogen? |
| |
|
K. Schütt, A. Savvaidis, P. Boor, V. Jankowski, K. Lysaja, J. Flöge, N. Marx, G. Schlieper (Aachen) |
|
|
Diskussion |
|
(V39) |
Evaluation of cation channels from the TRPC family as targets for antiplatelet drugs |
| |
|
J. E. Camacho Londoño, D. Schumacher, M. T. Harper, J. Camacho Londoño, S. E. Philipp, A. Dietrich, V. Flockerzi, A. W. Poole, L. Birnbaumer, M. Freichel (Heidelberg, Homburg, München; Cambridge, Bristol, UK; Buenos Aires, AR) |
|
|
Diskussion |
|
(V40) |
Importance of endothelial tumor suppressor p53 expression for venous thrombus formation and resolution in mice: effect of age |
| |
|
T. Bauer, A. Mann, T. Schönfelder, L. Hünig, S. Konstantinides, T. Münzel, P. Wenzel, K. Schäfer (Mainz) |
|
|
Diskussion |
|
(V41) |
Absence of Transforming Growth Factor-β1 in murine platelets reduces neointima formation without affecting thrombosis |
| |
|
E. Schütz, M. Bochenek, D. Riehl, T. Münzel, M. Bosmann, K. Schäfer (Mainz) |
|
|
Diskussion |
|
(V42) |
Platelet surface expression of SDF-1 is associated with clinical outcomes in patients with cardiovascular disease |
| |
|
D. Rath, M. Chatterjee, K. A. L. Müller, M. Droppa, F. Stimpfle, O. Borst, C. S. Meyer-Zürn, M. Gawaz, T. Geisler (Tübingen) |
|
|
Diskussion |